Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Paxalisib Combined With a Ketogenic Diet and Metformin for Glioblastoma
NCT05183204Phase 2Completed
- Sponsor
- Weill Cornell Medicine
- Start
- Feb 2022
- Primary completion
- Aug 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of paxalisib in glioblastoma (GBM), sponsored by Weill Cornell Medicine. Started Feb 2022; status: completed.
02
Drugs
paxalisib
03
Conditions
glioblastoma (GBM)
Beyond the preview
Go deeper on NCT05183204.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05183204.